REG - Oxford Biomedica PLC - Result of AGM

Oxford BioMedicaAnnouncement

07/05/2026 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260507:nRSG4909Da&default-theme=true

RNS Number : 4909D  Oxford Biomedica PLC  07 May 2026

 

OXB

Result of Annual General Meeting

 

Oxford, UK - 07 May 2026: OXB (LSE: OXB) (the "Company"), a global quality
and innovation-led cell and gene therapy CDMO, today announces that all
proposed resolutions were duly passed at its Annual General Meeting ("AGM"),
held at 3 pm on 07 May 2026 in Oxford. As proposed in the Notice of AGM, all
resolutions were decided by poll vote.

 

The full text of all the resolutions can be viewed in the Notice of AGM by
visiting the Company's website at www.oxb.com (http://www.oxb.com/)

 

Copies of the document setting out the above resolutions passed at the 2026
AGM have been submitted to the National Storage Mechanism and will shortly be
available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism)

 

On the Record Date (05 May 2026) there were 120,920,518 ordinary shares of 50
pence each in issue, each carrying one vote per share.

 

                                                                                       Votes For (incl. votes at the Chair's discretion)                    Votes Against                                                      Votes Withheld*                               Total votes cast**                     Result

                                                                                                                                          % of votes cast                                                    % of votes cast

      Resolutions
      Ordinary resolutions
 1    To receive and adopt the Company's Annual Report and accounts for the                          88,022,096                           99.98%                                 14,253                      0.02%
      financial year ended 31 December 2025, the Directors' Report, and the Report

      of the Independent Auditors on those accounts and reports.

                                                                                                                                                                                                                                                                                                                    PASS

                                                                                                                                                                                                                               149,975                                       88,036,349
 2    To receive the Directors' Remuneration Report and the Report of the                            77,910,043                           88.51%                          10,114,321                         11.49%
      Independent Auditors on the auditable part of the Remuneration Report

      (excluding the Directors' Remuneration Policy) set out at pages 90 to 112 of                                                                                                                                                                                                                                  PASS
      the Annual Report for the financial year ended 31 December 2025.

                                                                                                                                                                                                                               161,960                                       88,024,364
 3    To reappoint Dr. Roch Doliveux as a Director of the Company.                                   85,639,916                           97.24%                            2,431,539                        2.76%                                114,869                                  88,071,455               PASS
 4    To reappoint Dr. Frank Mathias as a Director of the Company.                                   86,374,661                           98.07%                            1,696,798                        1.93%                                114,865                                  88,071,459               PASS
 5    To reappoint Peter Soelkner as a Director of the Company.                                      85,669,982                           97.27%                            2,401,339                        2.73%                                115,003                                  88,071,321               PASS
 6    To reappoint Professor Dame Kay Davies as a Director of the Company.                           85,671,463                           97.28%                            2,399,858                        2.72%                                                                                                  PASS

                                                                                                                                                                                                                               115,003                                       88,071,321
 7    To reappoint Colin Bond as a Director of the Company.                                          87,273,801                           99.09%                               797,520                       0.91%                                115,003                                  88,071,321               PASS
 8    To reappoint Dr. Lucinda Crabtree as a Director of the Company.                                88,047,431                           99.97%                                 24,028                      0.03%                                114,865                                  88,071,459               PASS
 9    To reappoint Laurence Espinasse as a Director of the Company.                                  88,046,231                           99.97%                                 25,093                      0.03%                                115,000                                  88,071,324               PASS
 10   To reappoint Namrata Patel as a Director of the Company.                                       88,045,714                           99.97%                                 25,610                      0.03%                                115,000                                  88,071,324               PASS
 11   To reappoint Dr. Heather Preston as a Director of the Company.                                 85,236,452                           96.78%                            2,834,872                        3.22%                                115,000                                  88,071,324               PASS

 12   To reappoint PricewaterhouseCoopers LLP as auditors of the Company from the                    88,052,667                           99.98%                                 17,899                      0.02%                                                                                                  PASS
      conclusion of the 2026 AGM until the conclusion of the next AGM of the Company

      at which the accounts are laid.

                                                                                                                                                                                                                               115,758                                       88,070,566
 13   To authorise the Audit Committee for and on behalf of the Board to determine                   88,054,882                           99.98%                                 16,778                      0.02%                                                                                                  PASS
      the auditors' remuneration.

                                                                                                                                                                                                                               114,664                                       88,071,660
 14   To authorise the Directors to allot shares.                                                    87,589,834                           99.46%                               478,537                       0.54%                                117,953                                  88,068,371               PASS
      Special resolutions
 15   To authorise the Directors to disapply pre-emption rights.                                     87,247,698                           99.07%                               819,891                       0.93%                                118,735                                  88,067,589               PASS
 16   To authorise the Directors to further disapply pre-emption rights for                          87,103,359                           98.90%                               968,950                       1.10%                                                                                                  PASS
      acquisitions and specified capital investments.

                                                                                                                                                                                                                               114,015                                       88,072,309
 17   To permit the Directors to convene general meetings (other than annual general                 87,482,967                           99.33%                               590,744                       0.67%                                                                                                  PASS
      meetings) on not less than 14 days' notice.

                                                                                                                                                                                                                               112,613                                       88,073,711

* A vote withheld is not a vote in law and is not counted towards votes cast
in respect of a resolution.

** Total does not include withheld votes.

 

-Ends-

 

Enquiries:

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0)
1865 783 000 / E: cosec@oxb.com (mailto:cosec@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE 250 and a FTSE4Good constituent, is headquartered in Oxford, UK.
It has development and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at
www.oxb.com (http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSSIFIWEMSEII



            Copyright 2019 Regulatory News Service, all rights reserved